254 related articles for article (PubMed ID: 11249551)
21. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
Revicki DA
Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
[TBL] [Abstract][Full Text] [Related]
22. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine and risperidone.
Love RC; Kelly DL
Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
[No Abstract] [Full Text] [Related]
24. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of olanzapine: an overview of pivotal clinical trials.
Beasley CM; Tollefson GD; Tran PV
J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
[TBL] [Abstract][Full Text] [Related]
26. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
[TBL] [Abstract][Full Text] [Related]
27. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
28. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Gothelf D; Apter A; Reidman J; Brand-Gothelf A; Bloch Y; Gal G; Kikinzon L; Tyano S; Weizman R; Ratzoni G
J Neural Transm (Vienna); 2003 May; 110(5):545-60. PubMed ID: 12721815
[TBL] [Abstract][Full Text] [Related]
30. Amisulpride: a review of its use in the management of schizophrenia.
McKeage K; Plosker GL
CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
[TBL] [Abstract][Full Text] [Related]
31. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
32. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
33. Review of recent clinical studies with olanzapine.
Tollefson GD; Kuntz AJ
Br J Psychiatry Suppl; 1999; (37):30-5. PubMed ID: 10211139
[TBL] [Abstract][Full Text] [Related]
34. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
35. Service use and costs of treating schizophrenia with atypical antipsychotics.
Lewis M; McCrone P; Frangou S
J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine. Keep an eye on this neuroleptic.
Can Fam Physician; 2000 Feb; 46():322-6, 330-6. PubMed ID: 10690489
[TBL] [Abstract][Full Text] [Related]
38. Atypical neuroleptics in child and adolescent psychiatry.
Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E
Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I9-19. PubMed ID: 11140784
[TBL] [Abstract][Full Text] [Related]
39. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Glazer WM
J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
